Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar.

Alaa Abdullah Rahhal, Ahmed Awaisu, Kawthar M Tawengi, Safae AbuYousef, Lylia Mekideche

Abstract readObservational Study

In one paragraph

Observational study in International journal of clinical pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 83% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alaa Abdullah RahhalQatar University, Doha, Qatar.

Ahmed AwaisuQatar University, Doha, Qatar. aawaisu@qu.edu.qa.

Kawthar M TawengiQatar University, Doha, Qatar.

Safae AbuYousefQatar University, Doha, Qatar.

Lylia MekidecheQatar University, Doha, Qatar.

Qatar University · QA

Funding

Hamad Medical Corporation 16228/16

6 · The paper itself

Abstract

Background Digoxin is a cardiac glycoside that is recommended by clinical practice guidelines to be used in patients with heart failure with reduced ejection fraction (HFrEF) who still have persistent symptoms despite optimal medical therapy. However, this recommendation is based on limited and old trial data. Moreover, pharmacoepidemiologic studies are important in determining the prevalence of digoxin use and factors influencing this. Objective This study aimed to determine the prevalence and the predictors of digoxin utilization among patients with HFrEF with or without atrial fibrillation (AF) in Qatar. Setting Heart Hospital, a specialized tertiary care center in Qatar. Methods A retrospective observational study was conducted using Cerner electronic medical records. Subjects included 736 patients admitted between January 1, 2013 and December 31, 2014 with the diagnosis of HFrEF with or without AF. Two groups of patients were studied: digoxin users and digoxin non-users at index hospitalization until discharge. Univariate and multivariate binary logistic regression analyses were conducted to determine the predictors of digoxin prescription. Data analyses were performed using IBM SPSS

Indexed as

AdultAgedAged, 80 and overCardiotonic AgentsDigoxinDrug UtilizationFemaleForecastingHeart FailureHumansMaleMiddle AgedPrevalenceQatarRetrospective StudiesStroke VolumeCardiotonic AgentsDigoxinAtrial fibrillationDigoxinHeart failurePredictorsPrescriptionQatarRetrospective study

Identifiers

PMID28823072

DOI10.1007/s11096-017-0526-3

OpenAlexW2748261488

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.